Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) Stock Information | RedChip

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) Listen to this Section


$1.39
N/A ( 0% ) 7.7K

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derivedĀ from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

Market Data


Open


$1.39

Previous close


$1.39

Volume


7.7K

Market cap


$19.73M

Day range


$1.36 - $1.45

52 week range


$1.36 - $2.36

Insider Ownership Transactions

Total Amount Purchased: -1,106.00 | $ -1,537.34

Date Type Amount Purchased Purchaser
2023-12-28 Sale -72.00 Young Caroline
2023-12-28 Sale -72.00 Jones James
2023-12-06 Sale -55.00 Jones James
2023-12-06 Sale -352.00 Hamm John M.
2023-12-06 Sale -55.00 Young Caroline
2023-12-06 Sale -55.00 KAZIMI A J
2023-11-17 Sale -280.00 Krogulski Kenneth
2023-11-03 Sale -55.00 Young Caroline
2023-11-03 Sale -55.00 Jones James
2023-11-03 Sale -55.00 KAZIMI A J

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Mar 26, 2024
4 Insider transactions 1 Mar 26, 2024
4 Insider transactions 1 Mar 26, 2024
ars Annual reports 1 Mar 22, 2024
8-k 8K-related 19 Mar 20, 2024
def Proxies and info statements 6 Mar 13, 2024
10-k Annual reports 114 Mar 13, 2024
8-k 8K-related 16 Mar 05, 2024
4 Insider transactions 1 Dec 28, 2023
4 Insider transactions 1 Dec 28, 2023

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.